Concepedia

John M. Lambert

JM

Statistics

Publications

97

Citations

8.8K

H-Index

47

Active since

1977

Affiliations

ImmunoGen (United States)(Current)

Dana-Farber Cancer Institute

Harvard University

University of California, Davis

PAREXEL International (United Kingdom)

John M. Lambert is an author at ImmunoGen (United States) specializing in pharmacy, antibody conjugates, and pharmacology.

ORCID

Publications per year

1977–2022

97

Publications

97

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.7K citations

, , +17

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

John M. Lambert, Ravi Chari · Journal of Medicinal Chemistry · 2014 · 532 citations

, , +17

Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry

Lintao Wang, Godfrey Amphlett, Walter A. Blättler et al. · Protein Science · 2005 · 368 citations · Full text

, , +17

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism

John M. Lambert, Que T. Lambert, Gary W. Reuther et al. · Nature Cell Biology · 2002 · 326 citations

, , +11

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Xiuxia Sun, Jose F. Ponte, Nicholas C. Yoder et al. · Bioconjugate Chemistry · 2017 · 253 citations

, , +17

1–5 of 97